Dose-dependent differential resistance of inbred chicken lines to avian pathogenic Escherichia coli challenge.

Avian Pathol

a Division of Infection and Immunity, The Roslin Institute and Royal (Dick) School of Veterinary Studies , University of Edinburgh, Edinburgh, United Kingdom.

Published: April 2019

Avian pathogenic E. coli (APEC) cause severe respiratory and systemic disease. To address the genetic and immunological basis of resistance, inbred chicken lines were used to establish a model of differential resistance to APEC, using strain O1 of serotype O1:K1:H7. Inbred lines 7, 15I and C.B12 and the outbred line Novogen Brown were inoculated via the airsac with a high dose (10 colony-forming units, CFU) or low dose (10 CFU) of APEC O1. Clinical signs, colibacillosis lesion score and bacterial colonization of tissues after high dose challenge were significantly higher in line 15I and C.B12 birds. The majority of the 15I and C.B12 birds succumbed to the infection by 14 h post-infection, whilst none of the line 7 and the Novogen Brown birds developed clinical signs. No difference was observed after low dose challenge. In a repeat study, inbred lines 7 and 15I were inoculated with low, intermediate or high doses of APEC O1 ranging from 10 to 10 CFU. The colonization of lung was highest in line 15I after high dose challenge and birds developed clinical signs; however, colonization of blood and spleen, clinical signs and lesion score were not different between lines. No difference was observed after intermediate or low dose challenge. Ex vivo, the phagocytic and bactericidal activity of lung leukocytes from line 7 and 15I birds did not differ. Our data suggest that although differential resistance of inbred lines 7, 15I and C.B12 to APEC O1 challenge is apparent, it is dependent on the infectious dose. Research Highlights Lines 15I and C.B12 are more susceptible than line 7 to a high dose of APEC O1. Differential resistance is dose-dependent in lines 15I and 7. Phagocytic and bactericidal activity is similar and dose independent.

Download full-text PDF

Source
http://dx.doi.org/10.1080/03079457.2018.1562154DOI Listing

Publication Analysis

Top Keywords

lines 15i
20
15i cb12
20
differential resistance
16
high dose
16
clinical signs
16
dose challenge
16
resistance inbred
12
inbred lines
12
low dose
12
15i
9

Similar Publications

O-alkylation of the hydroxy compounds, including acetaminophen, starting compounds for the synthesis of the drug, and natural compounds with the bromides of dihydroartemisinin (DHA) and zerumbone, produced twenty novel ether conjugates 15a-j and 16a-j, respectively. Their structures were elucidated by 1D-, 2D-NMR, and HRMS data. Their in vitro cytotoxic activity was screened using three cancer cell lines: HepG2, HeLa, and PC-12.

View Article and Find Full Text PDF

Newcastle disease virus (NDV) recombinant expressing Marek's disease virus (MDV) glycoprotein B significantly protects chickens against MDV and NDV challenges.

Vaccine

September 2023

US National Poultry Research Center, Agricultural Research Service, United States Department of Agriculture, 934 College Station Road, Athens, GA 30605, USA. Electronic address:

Marek's disease (MD) is a highly contagious viral neoplastic disease of chickens caused by Marek's disease virus (MDV), resulting in significant economic losses to the poultry industry worldwide. The commonly used live and/or vectored MDV vaccines are expensive to produce and difficult to handle due to the requirement of liquid nitrogen for manufacturing and delivering frozen infected cells that are viable. In this study, we aimed to develop a Newcastle disease virus (NDV) vectored MDV vaccine that can be lyophilized, stored, and transported at 4 °C.

View Article and Find Full Text PDF

The mammalian target of rapamycin (mTOR) has been proved to be an effective target for cancer therapy. Two kinds of mTOR inhibitors, the rapalogs and mTOR kinase inhibitors (TORKi), have been developed and clinically validated in several types of malignancies. Compared with rapalogs, TORKi can exert better antitumor activity by inhibiting both mTORC1 and mTORC2, but the clinical development of current TORKi candidates has been relative slow, more TORKi with novel scaffold need to be developed to expand the current pipelines.

View Article and Find Full Text PDF

Structure-activity relationship study to improve cytotoxicity and selectivity of lonafarnib against breast cancer cells.

Arch Pharm (Weinheim)

April 2023

Department of Pharmaceutical Chemistry, Center for Molecular Biosciences Innsbruck, CCB-Centrum for Chemistry and Biomedicine, Institute of Pharmacy, University of Innsbruck, Innsbruck, Austria.

Lonafarnib is designed as a farnesyltransferase (FTase) inhibitor and displays inhibitory activities against a wide range of tumor cells. However, a major disadvantage is its unselective activity and high cytotoxicity against nonmalignant cells. Therefore, we structurally modified the terminal 4-methylpiperidine-1-carboxamide residue of lonafarnib and evaluated the antiproliferative effects of the resulting derivatives in Michigan Cancer Foundation - 7 (MCF-7) breast cancer cells as well as simian virus 80 (SV-80) fibroblasts.

View Article and Find Full Text PDF

Scaffold hopping of celastrol provides derivatives containing pepper ring, pyrazine and oxazole substructures as potent autophagy inducers against breast cancer cell line MCF-7.

Eur J Med Chem

April 2022

Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe District, Shenyang, 110016, China. Electronic address:

Three series of celastrol derivatives, namely, 6a-6i, 11a-11i and 15a-15i, were designed based on the scaffold hopping strategy. The derivatives were synthesized and biologically evaluated against five human tumor cell lines (i.e.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!